Background: Diffuse intrinsic pontine gliomas (DIPGs) and high-grade astrocytomas (HGA) continue to have dismal prognoses. The combination of cetuximab and irinotecan was demonstrated to be safe and tolerable in a previous pediatric phase 1 combination study. We developed this phase 2 trial to investigate the safety and efficacy of cetuximab given with radiation therapy followed by adjuvant cetuximab and irinotecan.
INTRODUCTION
While treatment advances have steadily improved the prognosis of most pediatric cancers, the survival rates for diffuse intrinsic pontine glioma (DIPG) and high-grade astrocytomas (HGA) remain dismal.
Together, they account for about 20% of pediatric brain tumors, yet are responsible for over 40% of the mortality in children with brain tumors. 1 Pediatric HGA, while molecularly different from adult HGA, 2, 3 have similarly poor outcomes with 3-year progression-free survival (PFS) of 13-22% for anaplastic astrocytomas and 7-15% for glioblastoma multiforme. [4] [5] [6] Standard of care for this population remains maximally safe surgical resection, involved-field radiation therapy, and chemotherapy; however, no optimal chemotherapy regimen has been established. [4] [5] [6] DIPG has even worse survival with a median survival rate under 1 year. 7 Despite many attempts to improve outcomes, radiation therapy remains the only treatment with therapeutic benefits. 8 One-year PFS rate for DIPG continues to be approximately 10-15%. 9, 10 Cetuximab (Erbitux R ; Eli Lilly and Company, Indianapolis, IN) is a high-affinity chimeric monoclonal antibody to epidermal growth factor receptor (EGFR) that inhibits ligand receptor activation through competitive ligand binding and induces internalization of the bound receptor. 11, 12 Cetuximab has demonstrated activity as a single agent and in combination with chemotherapy or radiation therapy in nonsmall cell lung cancer, head and neck squamous cell carcinoma, and KRAS wild-type colorectal cancer. [13] [14] [15] [16] [17] The EGFR pathway is frequently altered in adult HGA with overexpression, mutation, or amplification in approximately half of GBMs. [18] [19] [20] While pediatric HGA less commonly harbor EGFR amplification, increased expression is seen, suggesting that the EGFR pathway is a potential therapeutic target in HGA. 2, 21, 22 Despite limited single-agent activity in HGA, [23] [24] [25] irinotecan has modest activity against HGA in combination with other chemotherapies. [26] [27] [28] The addition of cetuximab to irinotecan enhances the antitumor activity of irinotecan in preclinical 29 and clinical investigations of colorectal cancer. 13, 14 Single-agent cetuximab induces objective tumor responses in adult HGA. 30 The Pediatric Oncology Experimental Therapeutics Investigators' Consortium performed the pediatric phase I study of cetuximab in combination with irinotecan, 31 which included primary central nervous system (CNS) tumors. The study established cetuximab 250 mg/m 2 weekly plus irinotecan 16 mg/m 2 /day as the pediatric recommended phase II dosing with manageable toxicities including hematologic, diarrhea, nausea, vomiting, and rash. 31 Twelve of 26 (46.2%) patients with CNS tumors had clinical benefit, with two patients having confirmed sustained partial responses. Due to the activity seen in the patients with CNS tumors, specifically HGA, we performed this phase II study in children with newly diagnosed HGA and DIPG evaluating the efficacy of cetuximab with radiation followed by weekly cetuximab with irinotecan.
MATERIALS AND METHODS

Subject eligibility
Patients of 3-21 years of age with newly diagnosed HGA or DIPG were eligible. The diagnosis of HGA was confirmed histologically by an institutional pathologist. Patients with DIPG were eligible based on classic clinical findings and radiologic diagnosis (magnetic resonance imaging [MRI]). Therapy was required to start within 42 days of resection or biopsy or from radiologic diagnosis in patients with HGA or DIPG. Other eligibility criteria included performance score ≥50 and adequate hematopoietic, hepatic, and renal functions. Patients were excluded if they had leptomeningeal or extraneural metastases, prior chemotherapy or radiation, prior therapy with an EGFR pathway targeted medicine, history of severe infusion reaction to a monoclonal antibody, uncontrolled cardiac disease, or known Gilbert's syndrome.
The study was approved by the institutional review boards/ institutional ethics committees at each institution. All patients or parents/legal guardians provided written informed consent; assent was obtained from patients when appropriate, in accordance with local guidelines.
Study design
The primary objectives were to determine the proportion of patients with HGA and DIPG achieving 1-year PFS by receiving cetuximab and external beam radiation therapy followed by cetuximab and irinotecan, and to determine the safety of weekly cetuximab in conjunction with involved field external beam radiation therapy. Secondary objectives were to estimate the time to progression (TTP) and overall sur- 
Patient evaluation
Within 30 days prior to starting therapy, a history, physical, laboratory studies, and imaging were obtained. During the first phase, physical exams and laboratories were performed weekly. During the second phase, physical exams and laboratories were performed prior to the start of each cycle. Disease evaluations with MRI were obtained prior to the second phase of therapy and then every third cycle thereafter. Following the completion of therapy, MRIs were obtained every 3 months for 1 year, and then every 3 months until 42 months after completion of therapy or disease progression. Response was evaluated in two dimensions using modified MacDonald Criteria by the institution. 32 Patients were followed for relapse and survival outcomes after protocol-prescribed therapy was completed.
Dose modifications
Toxicities were assessed throughout the study via the NCI Common Terminology Criteria for Adverse Event (CTCAE version 3.0). All toxicities were collected during treatment and for 30 days after the last dose of cetuximab. Grade 1 or 2 cetuximab infusion reactions required a 50% reduction in infusion rate; grade 3 or 4 infusion reactions required permanent discontinuation of cetuximab. Cetuximab-related rash was managed symptomatically. Cetuximab was held for at least grade 3 acneiform rash. Cetuximab was reduced by 50 mg/m 2 with recurrence and discontinued for more than 2 weeks treatment delay or three dose reductions were required. Diarrhea prophylaxis with an oral cephalosporin was permitted, and loperamide usage for diarrhea was encouraged. Irinotecan was dose reduced by 2 mg/m 2 /day for grade 3-4 diarrhea or for >7 days delay due to hematopoietic toxicity and held for elevated total bilirubin until <2.0 mg/dl.
Statistical design and analysis
A single-stage design with 80% power and 5% type I error was utilized for each cohort. For the DIPG cohort, the progression-free proportion at 1 year was deemed unacceptable if <10% and promising if ≥30%. If at least six of the planned 25 patients were alive and progression free at 1 year, the treatment would be declared worthy of further testing.
The HGA cohort required a progression-free proportion of >60% to be deemed promising and would be unacceptable if <35%. 4 If at least 14 of the planned 26 patients were alive and progression free at 1 year, the treatment would be worthy of further testing.
PFS at 1 year was assessed for DIPG and HGA separately and defined as the proportion of patients who remained alive and progression free 1 year after the initiation of therapy; remaining patients were censored at the date of last follow-up. All patients who received at least 1 day of therapy were evaluable for response. Those who were alive and progression free at 1 year by clinical and imaging assessments were considered progression free for the primary endpoint. Patients who withdrew consent for further study treatment but had progression within 6 months of withdrawal were considered as progressing on their date of progression. Those patients who withdrew and had unknown progression date or progression more than 6 months after withdrawal were censored at the date of last treatment. One patient withdrew consent and was lost to follow-up.
TTP was defined similarly to PFS except the three patients who died without documented progression were censored at the date of death. OS was defined as time from therapy start to death or last follow-up. Event-free survival (EFS) was defined similarly to PFS except patients who withdrew consent or stopped study protocol due to toxicity were assessed as events on the day of last treatment. OS, PFS, and TTP were analyzed using Kaplan-Meier and log-rank (MantelCox) analyses. Statistical analyses were performed using R version 3.1.2 (www.r-project.org) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA).
Tumor tissue analysis
Paraffin-embedded tumor sections were obtained from 19 of 23 patients who underwent surgery (18 HGA and one DIPG). Snapfrozen tumor from primary biopsy or resection was obtained from nine patients. One patient with DIPG had snap-frozen tissue available without paraffin tumor specimen. Genetic markers, EGFR copy number amplification, and KRAS mutation were screened in the samples as exploratory aims. 33,34
Evaluation of EGFR copy number by FISH
Formalin-fixed, paraffin-embedded (FFPE) tissue slides were evaluated for EGFR copy number by a dual-color FISH assay using the Vysis LSI EGFR SpectrumOrange/CEP7 SpectrumGreen probe set (Abbott Molecular; Cat. #05J48-001). 35 
KRAS sequencing
DNA was extracted from snap-frozen or FFPE material. DNA was PCR amplified with forward (5 ′ AAGGCCTGCTGAAAATGAC) and reverse (5 ′ TGGTCCTGCACCAGTAATATG) KRAS exon 2 primers. The purified PCR products were sequenced using an ABI 3730 automated sequencer.
Immunohistochemistry
Immunohistochemistry analyses were used to measure protein expression of EphA2 and phospho-AKT (pAKT), previously identified as positive and negative predictive markers for cetuximab responsiveness. 36, 37 Sections were deparaffinized, antigens unmasked, and stained for EphA2 (Spring Bioscience, Pleasanton, CA; rabbit clone SP169; Cat. #M4690; 1:200) and pAKT (Cell Signaling, Danvers, MA; rabbit polyclonal; Cat. #3787; Lot #8; 1:50). Scoring of pAKT and EphA2 IHC was performed as previously published. 37,38
Gene expression analysis
Snap-frozen tumor samples were analyzed using the Human Genome U133plus2 Array (Affymetrix) platform as described previously. 39 mRNAs corresponding to predictive markers implicated in cetuximab responsiveness were selected (see Supplementary Table S1 for list of mRNAs, corresponding probe sets, and PMID for publications reporting cetuximab treatment association). Samples were dichotomized into high (>mean) and low (<mean) expression for Kaplan-Meier analyses.
TA B L E 1 Patient characteristics
Number of patients (%)
Rash-associated cytokine analysis
As the development of rash during EGFR-directed therapies can correlate with clinical response, 40 serum was collected from all patients prior to the initial dose of cetuximab. Additional serum was collected with the development of rash and with any progression of rash. Control samples were collected from patients without rash prior to each of the first four cycles of cetuximab/irinotecan. Samples were assayed for a panel of 67 inflammation/immunity-related cytokines and peptides using a multiplex bead-based immunoassay system as described previously. 41, 42 The quantity of cytokines found in serum samples was analyzed using paired t-test (P < 0.05 and Log2 Fold change >0.5 or ←0.5) to compare pre-and posttreatment protein levels. 43 Pretreatment cytokine expression was compared to post cycle 1 expression in eight patients who did not develop rash. 
RESULTS
Patient characteristics
Efficacy and survival
Forty-four patients were eligible for evaluation of the primary outcome, the number of patients progression free at 1 year. Five patients with HGA (25%) and six with DIPG (24%) had not progressed at 1 year, meeting the predetermined criteria for a promising regimen for the DIPG stratum only. As 14 of the patients with HGA had progressed prior to 1 year, it was determined that the study would not meet the predetermined endpoint, and the stratum was closed before completing planned enrollment. At last follow-up, five patients with HGA and one with DIPG remained alive at 25-45 months (HGA) and 42 months (DIPG) from start of treatment.
For the 25 patients with DIPG, the median PFS and TTP were the same at 7.12 months (95% CI: 6.89-12.5) with a 1-year PFS based on Kaplan-Meier estimate of 29.6% (95% CI: 15-58). The median PFS and TTP for the 19 patients with HGA were also the same at 9.02 months (95% CI: 8.52-11.8) with a 1-year PFS of 18% (95% CI: 6-50) (Fig. 1A) .
The median EFS for HGA was 8.9 months (95% CI: 5. (Fig. 1B) .
Thirteen patients (six DIPG and seven HGA) completed the full 10 cycles of cetuximab and irinotecan. Four patients (three DIPG and one HGA) received therapy beyond 10 cycles at the discretion of the physician and family. One patient with DIPG remained on therapy for 39 cycles (over 3 years) until progression of disease.
Toxicity
Cetuximab combined with radiation therapy was well tolerated. The majority of toxicities were grade 1 and 2, with diarrhea, hypokalemia, and lymphopenia being the most common therapy-related adverse events (possibly, probably, or definitely attributed to study therapy) and the most frequent grade 3-4 events ( Table 2) . Gastrointestinal complaints, specifically diarrhea, nausea, and vomiting, occurred frequently in 68-75% of patients; but grade 3 toxicity was ≤15%, and there were no grade 4 events. Anemia occurred in almost half of all patients, but was mainly grade 1-2. Thrombocytopenia was only grade 1 and occurred in 11% of patients.
Electrolyte abnormalities were common but generally mild. Development of rash, either acneiform and/or desquamation, was seen in the majority of patients (60% and 53.3%, respectively); however, grade 3 events were rare. Allergic reaction/hypersensitivity occurred in four patients (8.9%); half required permanent discontinuation of cetuximab.
There were 48 occurrences of missed or delayed treatment due to toxicity. No patient required dose reductions of cetuximab. Irinotecan was dose reduced in five patients: two for excessive diarrhea, two due to prolonged neutropenia, and one for elevated liver enzymes.
No patient required more than one dose reduction for diarrhea. One patient stopped therapy for excessive toxicity (diarrhea) attributed to irinotecan.
Tumor tissue analysis
Eighteen HGA and one DIPG tumors were analyzed. EGFR copy num- CI 2.1-139.3; log-rank P = 0.0079) (Fig. 2) .
Inflammatory cytokines in cetuximab-mediated rash
In patients who did not develop rash, MDC, IL-13, I309, TARC, and SDF-1a were increased following treatment compared to baseline (Table 3 ). Six inflammatory cytokines had increased expression in patients with rash compared to baseline (TGFa, GRO, MDC, PDGFa, PDGF-b, and IL-33). However, none of these expression alterations were significant when adjusted for "false discovery rate" (Table 4) .
Additional studies with an expanded sample size are needed to further investigate these findings. Development of rash did not affect OS (P = 0.38) or PFS (P = 0.52).
DISCUSSION
In this study, the addition of cetuximab to radiation therapy followed by cetuximab and irinotecan did not improve PFS in children with HGA based on predetermined statistical parameters. The 1-year median PFS of 18% is lower than historical controls including the recently published COG trials for newly diagnosed high-grade gliomas with a 1-year EFS rates of 38% and 49%. 5, 6 This disparity could be influenced by differences in the extent of resection in the various series.
While this trial was not designed to directly compare with other studies, it clearly did not meet the predetermined endpoint deserving further study and does not provide a therapeutic advantage to radiation therapy plus temozolomide with or without lomustine for pediatric HGA. 5, 6 In contrast, six patients with DIPG (28%) remained progression free at the 1-year time point and met the predefined study criterion, suggesting that this regimen may be of benefit in this population. While the study met the predetermined 1-year PFS end point for children with DIPG, over half of the patients still died within 1 year of diagnosis and the median PFS and OS were similar to recent DIPG trials. 9, 44 There was a single "outstanding responder" who was on study for over 3 years before ultimately progressing.
The combination of cetuximab with radiation therapy and irinotecan in this population was well tolerated. The toxicity was similar in this newly diagnosed population to the phase 1 heavily pretreated population. 31 Additionally, combining cetuximab with radiation did not Gene microarray analysis on a subset of patients with HGA demonstrated that those with decreased E-cadherin and ERBB3 expression had prolonged survival compared with those patients with expression at the mean level or higher. High E-cadherin and ERBB3 expression have been identified as a potential biomarker of sensitivity to cetuximab treatment in colorectal cancer. 47 Low E-cadherin and ERBB3 expression are markers of a mesenchymal phenotype, 48 associated with EGFR activation in GBM. 49 Given the small number of patients, this association with prolonged survival would need to be evaluated in a larger cohort. While this study did not aim to evaluate cetuximab's ability to induce ADCC, the microarray analysis demonstrated upregulation of genes involving immune activation, suggesting there was immune stimulation induced by this regimen. This may suggest a potential alternate mechanism of action of cetuximab.
Development of rash during EGFR-directed therapy correlates
with increased likelihood of clinical response, 40 although the biological mechanisms are unclear. The rash often can be controlled by steroids or other immunosuppressive agents, suggesting a role for systemic immune activation in this process. 50 Our analyses were unable to demonstrate a group of pro-inflammatory cytokines that were significantly altered with the development of the rash with cetuximab. However, this may be due to the small sample size or cytokines profiled. Additionally, in contrast to patients with colorectal cancer, the development of rash was not associated with improved survival. 40 The addition of an EGFR inhibitor to radiation and irinotecan may be an effective regimen for a portion of patients with newly diagnosed DIPG to provide longer PFS. Further work with preclinical DIPG models is needed to elucidate the mechanism of this regimen's antitumor effect. While this is a clinically tolerable regimen, it is time intensive and difficult to recommend for further study in these tumors.
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